NSCLC Pipeline

Nov 25, 2022

Non-small cell lung cancer (NSCLC) is the most common cancer, accounting for approximately 85% of the total lung cancers in the United States. Almost 230K new cases were diagnosed in 2022 alone. Moreover, significant deaths were recorded at the end of the same year, accounting for almost 130K deaths. As per DelveIn...

Nov 25, 2022

Lung Cancer presents a heavy health and economic burden in Asia, being the most common form of cancer, with 60% of the world’s lung cancers being diagnosed there. Lung cancer is also present in more than 30% of non-smokers in Asia, specifically in adenocarcinomas, which is a subtype largely defined by oncogenic dri...

Nov 15, 2022

Genentech’s gantenerumab Fails in Phase III Trial for Alzheimer’s Disease In yet another setback for an amyloid-targeting drug, Roche's Genentech division has reported disappointing top-line results from its highly anticipated phase III trial of gantenerumab in early Alzheimer's disease. The failure is entirely ...

May 01, 2020

Non-small cell lung cancer market is anticipated to increase in the 7MM from USD 9,730 million in 2017 by 2030. Worldwide, cancer claimed the lives of approximately 9.6 million people in 2018 as per WHO, with lung cancer being the most commonly diagnosed one and accounting for the highest number of deaths (1.76...